Abstract

Many studies indicate that an anthocyanin-rich diet has beneficial effects preventing metabolic disease. In the present study, the molecular mechanism underlying the antiobesity effect of consuming blackberry anthocyanins (BLA) and blueberry anthocyanins (BBA) was investigated in high-fat-diet- (HFD-) fed C57BL/6 mice. Sixty mice were administered a low-fat diet (LFD), a HFD, or a HFD plus orlistat, and BLA or BBA in their daily food for 12 weeks. As a result, the consumption of BLA and BBA inhibited body weight gain by 40.5% and 55.4%, respectively, in HFD-fed mice. The BLA and BBA treatments markedly reduced serum and hepatic lipid levels and significantly increased hepatic superoxide dismutase and glutathione peroxidase activities. In addition, the treatments effectively increased fecal acetate and butyrate levels and significantly attenuated expression of tumor necrosis factor TNF-α, interleukin-6, and nuclear factor-kappaB genes. Moreover, gas chromatography time-of-flight mass spectroscopy results suggested that BLA and BBA significantly affected the hepatic lipid and glucose metabolic pathways, including glycerophospholipid metabolism, glutathione metabolism, and the insulin-signaling pathway. Therefore, BLA and BBA ameliorated diet-induced obesity by alleviating oxidative stress and inflammation and accelerating energy expenditure.

Highlights

  • Obesity has been officially recognized as a chronic disease and continues to be a major global health challenge

  • C57BL/6 mice were fed a HFD supplemented with blackberry anthocyanins (BLA) or blueberry anthocyanins (BBA) at a dose of 200 mg/kg in daily food for 12 weeks to determine the antiobesity effects of BLA and BBA

  • No significant differences were observed in daily food intake (~2.8 g), the liver, or kidney throughout the experiment, whereas BLA and BBA significantly reduced the food utility and effectively increased the weight of liver tissue when expressed as a percentage of body weight (Table 1)

Read more

Summary

Introduction

Obesity has been officially recognized as a chronic disease and continues to be a major global health challenge. Phentermine, orlistat, liraglutide, lorcaserin, phentermine/topiramate extended release, and naltrexone sustained release (SR)/bupropion SR have been approved as antiobesity medications [3, 4]. These drugs cause unwanted side effects [3, 5]. Anthocyanins are water-soluble polyphenolic compounds commonly found in the daily diet, in pigmented fruits and vegetables [6, 7]. These substances have attracted attention recently for their potential pharmacological activities, including anti-inflammatory, antioxidative, and antiobesity effects [8, 9].

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call